Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

Next Previous
X
Search
Trial Profile

A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosgemcitabine palabenamide (Primary)
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors NuCana

    • Most Recent Events

    • 10 Mar 2020 According to a NuCana media release, in Dec 2019, the company has announced not to proceed with part two of this study, as, the company is prioritizing its resources on key programs of Acelarin in biliary tract cancer and NUC-3373 in colorectal cancer.
    • 10 Mar 2020 According to a NuCana media release, the data from this study is still be being analyzed and the findings remain preliminary and subject to change.
    • 10 Mar 2020 Results (n=45) from the part 1 of this study are presented in a NuCana media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top